Home|Journals Follow on Twitter| Subscribe to List

Directory for Medical Articles
 

Open Access

-

J App Pharm Sci. 2017; 7(8): 104-115


Inulin nanoparticles and silymarin counteract chlorpromazine-induced injury in the liver and kidney of rats

Mosaad A. Abdel-Wahhab; Nihad I. Eid; Lamiaa A. Ahmed; Ghada M. Ragab; Aziza A. El-Nekeety; Mohamed M. El-Hakim; Nabila S. Hassan.

Abstract
The aim of the current study was to evaluate the protective role of inulin nanoparticles (INPs) prepared by the emulsion method alone or plus silymarin (SIL) against chlorpromazine (CPZ)-induced hepatonephrotoxicity in rats. Eleven female Sprague-Dawley rats were treated orally for 3 weeks as follow: control group, the group treated with CPZ (38.7 mg/kg. b.w in 1 ml saline each 72 h), the groups treated with INPs at low (100 mg/kg b.w) or high (200 mg/ kg b.w) dose, the group treated with SIL (50 mg/kg b.w), the groups treated with SIL plus INPs at the tow doses and the groups treated with CPZ plus SIL and INPs at the tow tested doses. At the end of treatment period, blood and tissue samples were collected for different biochemical and histological analyses. The results indicated that CPZ induced significant disturbances in liver and kidney function indices, oxidative stress markers, lipid profile, antioxidant enzymes activity and DNNA fragmentation as well as histological changes in liver and kidney. SIL alone or plus INPs alone at the low or high doses did not induce any significant changes in all the tested parameters of histological picture of the liver and kidney. SIL and INPs at the tow tested doses succeeded to induce a significant protection against CPZ-induce hepatonephrotoxicity due to their antioxidant activity and the role of INPs in enhancement the solubility of SIL. It could be concluded that INPs is a promise drug delivery and could prevent the liver and kidney injury induced by CPZ.

Key words: Chlorpromazine;Inulin naopartices;silymarin;liver;kidney;oxidative stress


Full text links

Share this Article




ScopeMed Home
Follow ScopeMed on Twitter
Article Tools
Job Opportunities/Service Offers
eJPort Journal Hosting
About ScopeMed
Terms & Conditions
Privacy Policy
Suggest a Journal
Publisher Login
Contact Us

The articles in Scopemed are open access articles licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright ScopeMed Information Services.
Scopemed Buttons